nach oben

Journal of Cancer Survivorship

Erschienen in:

10.03.2020

Functional connectome biotypes of chemotherapy-related cognitive impairment

verfasst von: Shelli R. Kesler, Melissa L. Petersen, Vikram Rao, Rebecca A. Harrison, Oxana Palesh

Erschienen in: Journal of Cancer Survivorship | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Cancer-related cognitive impairment (CRCI) is a common neurotoxicity among patients with breast and other cancers. Neuroimaging studies have demonstrated measurable biomarkers of CRCI but have largely neglected the potential heterogeneity of the syndrome.

Methods

We used retrospective functional MRI data from 80 chemotherapy-treated breast cancer survivors to examine neurophysiologic subtypes or “biotypes” of CRCI. The breast cancer group consisted of training (N = 57) and validation (N = 23) samples.

Results

An unsupervised clustering approach using connectomes from the training sample identified three distinct biotypes. Cognitive performance (p < 0.05, corrected) and regional connectome organization (p < 0.001, corrected) differed significantly between the biotypes and also from 103 healthy female controls. We then built a random forest classifier using connectome features to distinguish between the biotypes (accuracy = 91%) and applied this to the validation sample to predict biotype assignment. Cognitive performance (p < 0.05, corrected) and regional connectome organization (p < 0.005, corrected) differed significantly between the predicted biotypes and healthy controls. Biotypes were also characterized by divergent clinical and demographic factors as well as patient reported outcomes.

Conclusions

Neurophysiologic biotypes may help characterize the heterogeneity associated with CRCI in a data-driven manner based on neuroimaging biomarkers.

Implications for Cancer Survivors

Our novel findings provide a foundation for detecting potential risk and resilience factors that warrant further study. With further investigation, biotypes might be used to personalize assessments of and interventions for CRCI.

Janelsins MC, Kesler SR, Ahles TA, Morrow GR. Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int Rev Psychiatry. 2014;26(1):102–13. https://doi.org/10.3109/09540261.2013.864260.CrossRefPubMedPubMedCentral

Kesler SR, Rao A, Blayney DW, Oakley-Girvan IA, Karuturi M, Palesh O. Predicting long-term cognitive outcome following breast cancer with pre-treatment resting state fMRI and random forest machine learning. Front Hum Neurosci. 2017;11:555. https://doi.org/10.3389/fnhum.2017.00555.CrossRefPubMedPubMedCentral

van der Willik KD, Koppelmans V, Hauptmann M, Compter A, Ikram MA, Schagen SB. Inflammation markers and cognitive performance in breast cancer survivors 20 years after completion of chemotherapy: a cohort study. Breast Cancer Res. 2018;20(1):135. https://doi.org/10.1186/s13058-018-1062-3.CrossRefPubMedPubMedCentral

Bernstein LJ, McCreath GA, Komeylian Z, Rich JB. Cognitive impairment in breast cancer survivors treated with chemotherapy depends on control group type and cognitive domains assessed: a multilevel meta-analysis. Neurosci Biobehav Rev. 2017;83:417–28. https://doi.org/10.1016/j.neubiorev.2017.10.028.CrossRefPubMed

Shilling V, Jenkins V, Trapala IS. The (mis) classification of chemo-fog–methodological inconsistencies in the investigation of cognitive impairment after chemotherapy. Breast Cancer Res Treat. 2006;95(2):125–9. https://doi.org/10.1007/s10549-005-9055-1.CrossRefPubMed

Horowitz TS, Suls J, Treviño M. A call for a neuroscience approach to cancer-related cognitive impairment. Trends Neurosci. 2018;41(8):493–6. https://doi.org/10.1016/j.tins.2018.05.001.CrossRefPubMed

Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K, et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry. 2010;167(7):748–51. https://doi.org/10.1176/appi.ajp.2010.09091379.CrossRefPubMed

Morris SE, Cuthbert BN. Research domain criteria: cognitive systems, neural circuits, and dimensions of behavior. Dialogues Clin Neurosci. 2012;14(1):29–37.PubMedPubMedCentral

Shen CY, Chen VC, Yeh DC, Huang SL, Zhang XR, Chai JW, et al. Association of functional dorsal attention network alterations with breast cancer and chemotherapy. Sci Rep. 2019;9(1):104. https://doi.org/10.1038/s41598-018-36380-6.CrossRefPubMedPubMedCentral

10.

Feng Y, Zhang XD, Zheng G, Zhang LJ. Chemotherapy-induced brain changes in breast cancer survivors: evaluation with multimodality magnetic resonance imaging. Brain Imaging Behav. 2019;13:1799–814. https://doi.org/10.1007/s11682-019-00074-y.CrossRefPubMed

11.

Chen BT, Jin T, Patel SK, Ye N, Ma H, Wong CW, et al. Intrinsic brain activity changes associated with adjuvant chemotherapy in older women with breast cancer: a pilot longitudinal study. Breast Cancer Res Treat. 2019;176:181–9. https://doi.org/10.1007/s10549-019-05230-y.CrossRefPubMedPubMedCentral

12.

Apple AC, Schroeder MP, Ryals AJ, Wagner LI, Cella D, Shih PA, et al. Hippocampal functional connectivity is related to self-reported cognitive concerns in breast cancer patients undergoing adjuvant therapy. NeuroImage Clin. 2018;20:110–8. https://doi.org/10.1016/j.nicl.2018.07.010.CrossRefPubMedPubMedCentral

13.

Mo C, Lin H, Fu F, Lin L, Zhang J, Huang M, et al. Chemotherapy-induced changes of cerebral activity in resting-state functional magnetic resonance imaging and cerebral white matter in diffusion tensor imaging. Oncotarget. 2017;8(46):81273–84. https://doi.org/10.18632/oncotarget.18111.CrossRefPubMedPubMedCentral

14.

Miao H, Chen X, Yan Y, He X, Hu S, Kong J, et al. Functional connectivity change of brain default mode network in breast cancer patients after chemotherapy. Neuroradiology. 2016;58:921–8. https://doi.org/10.1007/s00234-016-1708-8.CrossRefPubMed

15.

Drysdale AT, Grosenick L, Downar J, Dunlop K, Mansouri F, Meng Y, et al. Resting-state connectivity biomarkers define neurophysiological subtypes of depression. Nat Med. 2017;23(1):28–38. https://doi.org/10.1038/nm.4246.CrossRefPubMed

16.

Marques P, Soares JM, Magalhaes R, Santos NC, Sousa N. The bounds of education in the human brain connectome. Sci Rep. 2015;5:12812–8. https://doi.org/10.1038/srep12812.CrossRefPubMedPubMedCentral

17.

Ingalhalikar M, Smith A, Parker D, Satterthwaite TD, Elliott MA, Ruparel K, et al. Sex differences in the structural connectome of the human brain. Proc Natl Acad Sci U S A. 2014;111(2):823–8. https://doi.org/10.1073/pnas.1316909110.CrossRefPubMed

18.

Sun J, Tong S, Yang GY. Reorganization of brain networks in aging and age-related diseases. Aging Dis. 2012;3(2):181–93.PubMed

19.

Krishnadas R, Kim J, McLean J, Batty GD, McLean JS, Millar K, et al. The envirome and the connectome: exploring the structural noise in the human brain associated with socioeconomic deprivation. Front Hum Neurosci. 2013;7:722. https://doi.org/10.3389/fnhum.2013.00722.CrossRefPubMedPubMedCentral

20.

Zhang Z, Allen G, Zhu H, Dunson D. Relationships between human brain structural connectomes and traits. bioRxiv. 2018. https://doi.org/10.1101/256933.

21.

Tuladhar AM, van Uden IW, Rutten-Jacobs LC, Lawrence A, van der Holst H, van Norden A, et al. Structural network efficiency predicts conversion to dementia. Neurology. 2016;86(12):1112–9. https://doi.org/10.1212/WNL.0000000000002502.CrossRefPubMedPubMedCentral

22.

Amidi A, Leemans A, Kesler SR, Agerbæk M, Wu LM, Zachariae R. Changes in brain structural networks and cognitive functions in testicular cancer patients receiving cisplatin-based chemotherapy. JNCI J Natl Cancer Inst. 2017;109(12):djx085-djx. https://doi.org/10.1093/jnci/djx085.CrossRef

23.

Bruno J, Hosseini SM, Kesler S. Altered resting state functional brain network topology in chemotherapy-treated breast cancer survivors. Neurobiol Dis. 2012;48(3):329–38. https://doi.org/10.1016/j.nbd.2012.07.009.CrossRefPubMedPubMedCentral

24.

Chiu GS, Boukelmoune N, Chiang ACA, Peng B, Rao V, Kingsley C, et al. Nasal administration of mesenchymal stem cells restores cisplatin-induced cognitive impairment and brain damage in mice. Oncotarget. 2018;9(85):35581–97. https://doi.org/10.18632/oncotarget.26272.CrossRefPubMedPubMedCentral

25.

Hosseini SM, Koovakkattu D, Kesler SR. Altered small-world properties of gray matter networks in breast cancer. BMC Neurol. 2012;12:28. https://doi.org/10.1186/1471-2377-12-28.CrossRefPubMedPubMedCentral

26.

Kesler SR, Blayney DW. Neurotoxic effects of anthracycline- vs nonanthracycline-based chemotherapy on cognition in breast cancer survivors. JAMA Oncol. 2016;2(2):185–92. https://doi.org/10.1001/jamaoncol.2015.4333.CrossRefPubMedPubMedCentral

27.

Kesler SR, Gugel M, Huston-Warren E, Watson C. Atypical structural connectome organization and cognitive impairment in young survivors of acute lymphoblastic leukemia. Brain Connect. 2016;6(4):273–82. https://doi.org/10.1089/brain.2015.0409.CrossRefPubMedPubMedCentral

28.

Kesler SR, Gugel M, Pritchard-Berman M, Lee C, Kutner E, Hosseini SM, et al. Altered resting state functional connectivity in young survivors of acute lymphoblastic leukemia. Pediatr Blood Cancer. 2014;61(7):1295–9. https://doi.org/10.1002/pbc.25022.CrossRefPubMedPubMedCentral

29.

Kesler SR, Noll K, Cahill DP, Rao G, Wefel JS. The effect of IDH1 mutation on the structural connectome in malignant astrocytoma. J Neuro-Oncol. 2017;131(3):565–74. https://doi.org/10.1007/s11060-016-2328-1.CrossRef

30.

Kesler SR, Ogg R, Reddick WE, Phillips N, Scoggins M, Glass JO, et al. Brain network connectivity and executive function in long-term survivors of childhood acute lymphoblastic leukemia. Brain connectivity. 2018;8(6):333–42. https://doi.org/10.1089/brain.2017.0574.CrossRefPubMedPubMedCentral

31.

Kesler SR, Watson CL, Blayney DW. Brain network alterations and vulnerability to simulated neurodegeneration in breast cancer. Neurobiol Aging. 2015;36(8):2429–42. https://doi.org/10.1016/j.neurobiolaging.2015.04.015.CrossRefPubMedPubMedCentral

32.

Glover GH, Lai S. Self-navigated spiral fMRI: interleaved versus single-shot. Magn Reson Med. 1998;39(3):361–8.CrossRefPubMed

33.

Ashburner J. SPM: a history. NeuroImage. 2012;62(2):791–800. https://doi.org/10.1016/j.neuroimage.2011.10.025.CrossRefPubMed

34.

Whitfield-Gabrieli S, Nieto-Castanon A. Conn: a functional connectivity toolbox for correlated and anticorrelated brain networks. Brain Connect. 2012;2(3):125–41. https://doi.org/10.1089/brain.2012.0073.CrossRefPubMed

35.

Behzadi Y, Restom K, Liau J, Liu TT. A component based noise correction method (CompCor) for BOLD and perfusion based fMRI. NeuroImage. 2007;37(1):90–101. https://doi.org/10.1016/j.neuroimage.2007.04.042.CrossRefPubMed

36.

Shen X, Tokoglu F, Papademetris X, Constable RT. Groupwise whole-brain parcellation from resting-state fMRI data for network node identification. NeuroImage. 2013;82:403–15. https://doi.org/10.1016/j.neuroimage.2013.05.081.CrossRefPubMed

37.

Smith SR, Servesco AM, Edwards JW, Rahban R, Barazani S, Nowinski LA, et al. Exploring the validity of the comprehensive trail making test. Clin Neuropsychol. 2008;22(3):507–18.CrossRefPubMed

38.

Delis DC, Kaplan E, Kramer JH. Delis-Kaplan executive function system. San Antonio: Psychological Corp; 2008.

39.

de Sousa MS, Malloy-Diniz LF, Hamdan AC. Validity convergent and reliability test-retest of the Rey Auditory Verbal Learning Test. Age (years). 2012;20(4.5):19.1.

40.

Aghakhani A, Chan EK. Test reviews: Bracken, BA, & Howell, K. (2004). Clinical assessment of depression. Odessa, FL: psychological assessment resources. J Psychoeduc Assess. 2007;25(4):416–22. https://doi.org/10.1177/0734282907300383.CrossRef

41.

Roth RM, Lance CE, Isquith PK, Fischer AS, Giancola PR. Confirmatory factor analysis of the behavior rating inventory of executive function-adult version in healthy adults and application to attention-deficit/hyperactivity disorder. Arch Clin Neuropsychol. 2013;28(5):425–34.CrossRefPubMedPubMedCentral

42.

Shen X, Finn ES, Scheinost D, Rosenberg MD, Chun MM, Papademetris X, et al. Using connectome-based predictive modeling to predict individual behavior from brain connectivity. Nat Protoc. 2017;12(3):506–18. https://doi.org/10.1038/nprot.2016.178.CrossRefPubMedPubMedCentral

43.

Shi T, Horvath S. Unsupervised learning with random forest predictors. J Comput Graph Stat. 2006;15(1):118–38. https://doi.org/10.1198/106186006X94072.CrossRef

44.

Breiman L. Random forests. Mach Learn. 2001;45(1):5–32. https://doi.org/10.1023/A:1010933404324.CrossRef

45.

Charrad M, Ghazzali N, Boiteau V, Niknafs A. NbClust: an R package for determining the relevant number of clusters in a data set. J Stat Softw. 2014;61(6):36. https://doi.org/10.18637/jss.v061.i06.CrossRef

46.

Benjamini Y, Yekutieli D. The control of the false discovery rate in multiple testing under dependency. Ann Stat. 2001;29(4):1165–88.CrossRef

47.

Zalesky A, Fornito A, Bullmore ET. Network-based statistic: identifying differences in brain networks. NeuroImage. 2010;53(4):1197–207. https://doi.org/10.1016/j.neuroimage.2010.06.041.CrossRefPubMed

48.

Liaw A, Wiener M. Classification and regression by randomForest. R News. 2002;2(3):18–22.

49.

Cohen J. Statistical power analysis for the behavioral sciences. Abingdon: Routledge; 2013.CrossRef

50.

Hosseini SM, Kesler SR. Multivariate pattern analysis of FMRI in breast cancer survivors and healthy women. J Int Neuropsychol Soc. 2014;20(4):391–401. https://doi.org/10.1017/S1355617713001173.CrossRefPubMed

51.

Sahnoune I, Inoue T, Kesler SR, Rodgers SP, Sabek OM, Pedersen SE, et al. Exercise ameliorates neurocognitive impairments in a translational model of pediatric radiotherapy. Neuro-Oncology. 2018;20(5):695–704. https://doi.org/10.1093/neuonc/nox197.CrossRefPubMed

52.

Seiler A, Murdock KW, Garcini LM, Chirinos DA, Ramirez J, Jackson B, et al. Racial/ethnic disparities in breast cancer incidence, risk factors, health care utilization, and outcomes in the USA. Curr Breast Cancer Rep. 2017;9(2):91–9. https://doi.org/10.1007/s12609-017-0247-6.CrossRef

53.

Stouten-Kemperman MM, de Ruiter MB, Koppelmans V, Boogerd W, Reneman L, Schagen SB. Neurotoxicity in breast cancer survivors >/= 10 years post-treatment is dependent on treatment type. Brain Imaging Behav. 2015;9(2):275–84. https://doi.org/10.1007/s11682-014-9305-0.CrossRefPubMed

54.

Ahles TA, Saykin AJ, McDonald BC, Furstenberg CT, Cole BF, Hanscom BS, et al. Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Treat. 2008;110(1):143–52. https://doi.org/10.1007/s10549-007-9686-5.CrossRefPubMed

55.

Stern Y. An approach to studying the neural correlates of reserve. Brain Imaging Behav. 2017;11(2):410–6. https://doi.org/10.1007/s11682-016-9566-x.CrossRefPubMedPubMedCentral

56.

Smith SM, Nichols TE, Vidaurre D, Winkler AM, Behrens TE, Glasser MF, et al. A positive-negative mode of population covariation links brain connectivity, demographics and behavior. Nat Neurosci. 2015;18(11):1565–7. https://doi.org/10.1038/nn.4125.

57.

Li M, Caeyenberghs K. Longitudinal assessment of chemotherapy-induced changes in brain and cognitive functioning: A systematic review. Neurosci Biobehav Rev. 2018;92:304–17. https://doi.org/10.1016/j.neubiorev.2018.05.019.CrossRefPubMed

58.

Finn ES, Scheinost D, Finn DM, Shen X, Papademetris X, Constable RT. Can brain state be manipulated to emphasize individual differences in functional connectivity? NeuroImage. 2017;160:140–51. https://doi.org/10.1016/j.neuroimage.2017.03.064.CrossRefPubMed

59.

Finn ES, Shen X, Scheinost D, Rosenberg MD, Huang J, Chun MM, et al. Functional connectome fingerprinting: identifying individuals using patterns of brain connectivity. Nat Neurosci. 2015;18(11):1664–71. https://doi.org/10.1038/nn.4135.CrossRefPubMedPubMedCentral

60.

Cornblath EJ, Lydon-Staley DM, Bassett DS. Harnessing networks and machine learning in neuropsychiatric care. Curr Opin Neurobiol. 2019;55:32–9. https://doi.org/10.1016/j.conb.2018.12.010.CrossRefPubMedPubMedCentral

Titel: Functional connectome biotypes of chemotherapy-related cognitive impairment
verfasst von: Shelli R. Kesler
Melissa L. Petersen
Vikram Rao
Rebecca A. Harrison
Oxana Palesh
Publikationsdatum: 10.03.2020
Verlag: Springer US
Erschienen in: Journal of Cancer Survivorship / Ausgabe 4/2020
Print ISSN: 1932-2259
Elektronische ISSN: 1932-2267
DOI: https://doi.org/10.1007/s11764-020-00863-1

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Functional connectome biotypes of chemotherapy-related cognitive impairment

Abstract

Purpose

Methods

Results

Conclusions

Implications for Cancer Survivors

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Implications for Cancer Survivors

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2020

Physical function in patients with resectable cancer of the pancreas and liver–a systematic review

A telephone-based education and support intervention for Rural Breast Cancer Survivors: a randomized controlled trial comparing two implementation strategies in rural Florida

Systematic review of cognitive sequelae of non-central nervous system cancer and cancer therapy

Effects of dietary and physical activity interventions on generic and cancer-specific health-related quality of life, anxiety, and depression in colorectal cancer survivors: a randomized controlled trial

The impact of breast cancer on physical activity from midlife to early older adulthood and predictors of change post-diagnosis

Systematic review of the effectiveness of self-initiated interventions to decrease pain and sensory disturbances associated with peripheral neuropathy

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie